Drug Trial Radar · NCT05790304
Study to Investigate Hepatic Impairment on PK, Safety, Tolerability of Camizestrant in Post-Menopausal Female Subjects
Last checked: Nov 20, 2026Latest source record: Mar 25, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
22
Actual
Start
Feb 20, 2023
Primary completion
Feb 22, 2024
Study completion Feb 22, 2024
Sponsor
- Lead sponsor
- AstraZenecaAstraZeneca (AZN)
- Sponsor type
- Industry
- First posted
- Mar 30, 2023
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Non randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Other
- FDA-regulated drug
- Yes
- Who can join
- Female only, from 50 years, up to 75 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
This will be a Phase I, multicentre, single-dose, non-randomized, open-label, parallel-group study to examine the PK, safety, and tolerability of camizestrant 75 mg in post-menopausal female participants with moderate or severe hepatic impairment compared with post-menopausal female participants with normal hepatic function. Participants will be enrolled within the following groups based on their CP classification score as determined at screening: * Group 1: Matched-control healthy participants with normal hepatic function. * Group 2: Participants with moderate hepatic impairment (CP Class B, score of 7 to 9). * Group 3: Participants with severe hepatic impairment (CP Class C, score of 10 to 15).
Conditions
- Hepatic Impairment
Interventions
CamizestrantDrug
Camizestrant 75 mg tablets. Experimental drug.
Primary outcomes
What the sponsor says the trial is designed to measure.
- PK parameters CmaxTime frame: 5 days
- PK parameters tmaxTime frame: 5 days
- PK parameters AUClast,Time frame: 5 days
- PK parameters AUCinf.;Time frame: 5 days
- PK parameters tlastTime frame: 5 days
- PK parameters t1/2λzTime frame: 5 days
- PK parameters CL/FTime frame: 5 days
- PK parameters Vz/F.Time frame: 5 days
Locations
4 sites in 3 countries. Site status is shown where the registry gives one.
Research Site
San Antonio, Texas
Research Site
San Antonio, Texas
Research Site
Sofia, Bulgaria
Research Site
Bratislava, Slovakia
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.